Continuous administration test from the Phase I/II clinical trials in hemophilia A patient of ACE910

Trial Profile

Continuous administration test from the Phase I/II clinical trials in hemophilia A patient of ACE910

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 28 Jul 2016 Results presented at the World Federation of Hemophilia 2016 World Congress, according to a Roche media release.
    • 28 Jul 2016 Results published in a Roche media release.
    • 28 Jul 2016 Results published in the New England Journal of Medicine, according to a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top